Company Filing History:
Years Active: 1994-2001
Title: William H. Darlington: A Pioneer in Therapeutic Innovations
Introduction
William H. Darlington, an esteemed inventor based in Kalamazoo, MI, has made significant contributions to the field of pharmaceuticals. With a portfolio of five patents, his work focuses particularly on therapeutically useful compounds that have broad implications for central nervous system disorders.
Latest Patents
Among his latest innovations are two groundbreaking patents. The first one pertains to therapeutically useful 2-aminotetralin derivatives, which detail the compounds and their pharmaceutically acceptable acid addition salts. This invention showcases his ability to create novel compounds that are vital for medical applications. The second patent involves the development of aryl substituted bicyclic amines, specifically as selective dopamine D3 ligands. These compounds, along with their suitable pharmaceutically acceptable salts, are designed to treat central nervous system disorders linked to dopamine D3 receptor activity.
Career Highlights
William H. Darlington has had a remarkable career, working with notable companies such as The Upjohn Company and Pharmacia & Upjohn Company. His collaborations in these organizations have positioned him as an influential figure in pharmaceutical research and development, particularly in the realm of new therapeutic agents.
Collaborations
Throughout his career, Darlington has collaborated with esteemed colleagues, including Arthur Glenn Romero and Chiu-Hong Lin. Their collective expertise has likely played a crucial role in advancing the innovative solutions that have emerged from their work together.
Conclusion
William H. Darlington exemplifies the spirit of innovation in pharmaceuticals. His patents focus on essential therapeutic compounds that are transforming the approach towards treating central nervous system disorders. With his impressive background and collaborations, Darlington continues to inspire future generations of inventors and researchers within the field.